Drug intelligence / Profile preview

pralatrexate + vitamin B12 + folic acid

Development stage: Unknown
Lead developer: Assertio
Modality: Small Molecules
Administration: Intravenous, Intramuscular, Oral

Overview

A therapeutic regimen combining pralatrexate (a folate analog metabolic inhibitor) with vitamin B12 and folic acid supplementation. This combination is designed to allow for effective cancer treatment while mitigating toxicity, particularly mucositis. Pralatrexate competitively inhibits dihydrofolate reductase (DHFR) and selectively enters cells expressing reduced folate carrier type 1 (RFC-1), which is overexpressed on certain cancer cells. The vitamin supplementation is specifically added to reduce treatment-related toxicities.

Targets

DHFR (Dihydrofolate reductase)FPGS (Folylpolyglutamate synthase, mitochondrial)

Beyond the preview

Go deeper on pralatrexate + vitamin B12 + folic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pralatrexate + vitamin B12 + folic acid.

Explore the full profile